Application of novel eye drops in treatment of dry eyes

Abstract

The invention discloses an application of novel eye drops in treatment of dry eyes. The novel eye drops contain alpha-MSH; the mass concentration of the alpha-MSH is 10<-4> to 10<-3>mg / ml; the novel eye drops are used for treating the dye eyes; and the optimized mass concentration of the alpha-MSH is 10<-4>mg / ml. By using the novel eye drops, experiment analysis on the breakup time of a tear film (BUT), schirmer test, fluorescein staining, grade and tear ferns is carried out on rats; an overall eyeball of each rat is extracted to be subjected to HE and periodic acid-Schiff (PAS) staining; and the fresh cornea of each rat is extracted to be subjected to real-time quantitative PCR detection of expression levels of interleukin-1beta and tumor necrosis factor-alpha m RNA in corneal tissues, so that the experiments prove that the eye drops containing alpha-MSH are capable of promoting schirmer in rats, prolonging the breakup time of the tear film, stabilizing the tear film, promoting corneal epithelium damage repair and goblet cell quantity repair, and relieving ocular surface inflammation, and are favorable for relieving lesions of the dry eyes.

Description

technical field [0001] The invention relates to the application of a medicine, in particular to the application of a novel eye drop for treating dry eye. Background technique [0002] Dry eye is a common ocular surface disease caused by various reasons, and its incidence is increasing day by day, seriously affecting people's vision and quality of life. At present, the research on dry eye in our country is still in its infancy, and there is a lack of effective methods for treating dry eye in the world. There is an urgent need to strengthen the research on dry eye, develop a treatment plan for dry eye according to its pathogenesis, and relieve the pain of dry eye patients. [0003] 15-35% of the world's population is accompanied by symptoms or signs of dry eye. In 2007, the International Dry Eye Working Group newly defined dry eye as: a multifactorial disease that can cause ocular discomfort, visual disturbance and tear film instability, damage to tear fluid and ocular surfa...

AI Technical Summary

Problems solved by technology

At present, artificial tear substitutes are commonly used clinically to relieve symptoms, but they are not suitable for moderate and severe dry eye diseases; autologous serum is suitable for moderate and severe dry eye diseases, but they cannot be widely used in clinical practice due to their limited storage; others such as glucocorticoids Long-term application has serious systemic side effects, etc.

Images